LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Akciju saraksts・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Slēgts

18.65 -0.16

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

18.53

Max

19.12

Galvenie mērījumi
By Trading Economics
Ienākumi	-2.2M -10M
Darbinieki	31
EBITDA	131K -10M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+69.51% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 24. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.1B 1.7B
Iepriekšējā atvēršanas cena	18.81
Iepriekšējā slēgšanas cena	18.65

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

3.165 / 3.5827 Atbalsts un pretestība

Corvus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. febr. 16:32 UTC

Peļņas

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

2026. g. 13. febr. 21:57 UTC

Peļņas

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

2026. g. 13. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 13. febr. 21:20 UTC

Peļņas

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

2026. g. 13. febr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

2026. g. 13. febr. 20:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 13. febr. 20:45 UTC

Tirgus saruna

Dollar Pares Down Early Losses -- Market Talk

2026. g. 13. febr. 20:39 UTC

Tirgus saruna

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

2026. g. 13. febr. 20:28 UTC

Tirgus saruna

Oil Settles Week Lower -- Market Talk

2026. g. 13. febr. 19:51 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026. g. 13. febr. 19:32 UTC

Tirgus saruna

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026. g. 13. febr. 19:32 UTC

Tirgus saruna

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026. g. 13. febr. 19:29 UTC

Peļņas

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

2026. g. 13. febr. 18:18 UTC

Iegādes, apvienošanās, pārņemšana

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

2026. g. 13. febr. 17:52 UTC

Peļņas

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

2026. g. 13. febr. 17:16 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026. g. 13. febr. 17:10 UTC

Iegādes, apvienošanās, pārņemšana

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

2026. g. 13. febr. 16:59 UTC

Peļņas

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

2026. g. 13. febr. 16:39 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

2026. g. 13. febr. 16:11 UTC

Peļņas

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

2026. g. 13. febr. 16:07 UTC

Tirgus saruna

Hungarian Forint Could Rise Further -- Market Talk

2026. g. 13. febr. 15:54 UTC

Peļņas

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

2026. g. 13. febr. 15:26 UTC

Tirgus saruna

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

2026. g. 13. febr. 15:01 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

2026. g. 13. febr. 15:00 UTC

Peļņas

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

2026. g. 13. febr. 14:50 UTC

Tirgus saruna

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

2026. g. 13. febr. 14:44 UTC

Peļņas

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

2026. g. 13. febr. 14:22 UTC

Tirgus saruna

Peļņas

Global Energy Roundup: Market Talk

2026. g. 13. febr. 14:21 UTC

Tirgus saruna

Peļņas

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

2026. g. 13. febr. 14:13 UTC

Tirgus saruna

U.S. Natural Gas Futures Move Lower -- Market Talk

Salīdzinājums

Cenas izmaiņa

Corvus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

69.51% augšup

Prognoze 12 mēnešiem

Vidējais 31.8 USD 69.51%

Augstākais 42 USD

Zemākais 27 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Corvus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Corvus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.165 / 3.5827Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.